ChromoCure, Inc. Expands Capabilities for CS300 Series Chromosomal Scanner as Part of Genome Research Agreement
April 09 2010 - 7:30AM
Marketwired
ChromoCure, Inc. (PINKSHEETS: KKUR) released today expanded
specifications and capabilities for its next generation chromosomal
scanner. The CS300 system now includes significant new features and
capabilities. The new technology being incorporated into the CS300
is a direct result of the company's recently announced relationship
with Genome Research Group. The base CS300 includes the following
base specifications: - Fully automated cell sample preparation
cycling, automated multi-patient, multi-sample cell application to
slide matrix array, On-Slide direct application of DNA-probes using
robotic micro-application, and user-selectable chromosome probe
types -- one probe or multiple simultaneous probes. Full
integration of de-paraffinization and cellular disaggregation of
tissue samples for non-cytology originated diagnostics. The
expanded CS300 feature set now includes:
- Aneuploidy scaling and cancer progression graphing and
DNA-index curve fitting
- Ability to detect and store cancer progression and remission
results over time
- Cancer remission and progression predictive algorithms using
aneuploidy scaling
- Animal scanning capability using species specific DNA-probes
for use in clinical trials of therapeutic models
- Time based daily progression and remission scanning and
analysis incorporated into therapeutic testing and model
- Expanded user reporting and graphing capabilities for
progression, remission, and clinical outcome projection
analysis
The Company recently announced its Joint Venture and Technology
Sharing Agreement with Genome Research Group. GRG's advanced
Therapeutic Modeling Protocols, together with ChromoCure's landmark
Chromosomal Scanning Technology, further strengthens the Company's
leadership in Cancer Detection, Therapy and Cure, and puts new
impetus to its groundbreaking Project Boveri: Finding the Cure. The
Company's proprietary Chromosomal Scanner systems have proven
accurate and efficient in the measurement of the unique genomic
characteristic found in 100% of all cancers and never found in
normal cells. The Company's detection technology has been proven to
have an effective accuracy of 100% for all cancers at all stages.
This is superior to other detection approaches presently relied
upon by pathologists, including genetic or protein biomarker
detection. About ChromoCure ChromoCure develops and provides
proprietary cancer detection systems and related therapeutic
technologies. The Company's proprietary CS200 Chromosomal Scanner
has been proven accurate and efficient in the measurement of the
unique genomic characteristic found in 100% of all cancers and
never found in normal cells. The Company's detection technology has
an effective accuracy of 100% for all cancers at all stages. The
Company believes its technology will become the worldwide gold
standard for cancer detection, progression measurement, and
research for both therapy and cure. The Company also applies its
technology and knowledge to cancer cure and therapeutics research.
Safe-Harbor Statement This release contains statements or
projections regarding future performance that are forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995. Actual results may differ materially from those
projected as a result of certain risks and uncertainties. The
company's filings contain various RISK FACTORS (and are
incorporated herein by reference) and should be read before any
investment decision.
ChromoCure, Inc. www.ChromoCure.com info@chromocure.com Tel
1.775.636.6548
Chromocure (CE) (USOTC:KKUR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Chromocure (CE) (USOTC:KKUR)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Chromocure Inc (CE) (OTCMarkets): 0 recent articles
More ChromoCure, Inc. News Articles